Renal Cell Carcinoma in Renal Transplant Patients

Ianhez, L E; Lucon, Marcos; Nahas, William Carlos; Sabbaga, E; Saldanha, Luiz Balthazar; Lucon, Antônio Marmo; Srougi, Miguel

doi:10.1016/j.urology.2006.11.007

Cited by 59 publications

(46 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…86 The spectrum of renal tumors associated with end-stage renal disease is quite varied and in single cases and small series clear cell renal cell carcinomas, papillary renal cell carcinomas, chromophobe renal carcinoma, collecting-duct carcinoma, tubulocystic carcinoma, angiomyolipoma, oncocytoma and mixed epithelial and stromal tumor have been reported. [87][88][89][90][91][92][93][94] In up to 70% of cases more than one tumor was present in a single kidney. 95 In a detailed study of 66 tumor-bearing kidneys from patients with end-stage renal disease, a wide spectrum of renal neoplasia was noted.…”

Section: Carcinoma Associated With End-stage Renal Diseasementioning

confidence: 99%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma. Clear cell, papillary and chromophobe carcinomas account for 85-90% carcinomas seen in routine practice. The remaining 10-15% of carcinomas consist of rare sporadic and hereditary tumors, some of which had been long recognized, but many of which only emerged as distinct entities in the decade leading up to the WHO publication. Collecting-duct carcinoma is a rare, often lethal form of carcinoma. Medullary carcinoma associated with sickle cell trait, has emerged as a distinctive tumor showing some overlapping features with upper tract urothelial carcinoma. Mucinous tubular and spindle-cell carcinoma and tubulocystic carcinoma were earlier considered as patterns of low-grade collecting-duct carcinoma, but are now recognized as separate tumor entities. Carcinomas associated with somatic translocations of TFE3 and TFEB comprise a significant proportion of pediatric renal carcinomas. Oncocytoid renal carcinomas in neuroblastoma survivors was recognized as a unique tumor category in the WHO classification. Renal carcinoma associated with end-stage renal disease is now recognized as having distinct morphological patterns and behavior. In addition there is a group of rare recently described carcinomas, including clear cell papillary carcinoma, oncocytic papillary renal cell carcinoma, follicular renal carcinoma and leiomyomatous renal cell carcinoma. It behooves the surgical pathologist to not only be capable of diagnosing the common forms of renal cancer, but also to be aware of the rare types of renal carcinoma, many of which have emerged in recent years.

show abstract

Section: Carcinoma Associated With End-stage Renal Diseasementioning

confidence: 99%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

show abstract

“…Radical nephrectomy were justified by a large lesion, a low functioning graft, two or more lesions, locally invasive tumor or diffuse graft infiltration on radiological studies [2]. In the recent years, partial nephrectomy (Nephron sparing surgery) has been performed widely with great success.…”

Section: Treatmentmentioning

confidence: 99%

“…In the recent years, partial nephrectomy (Nephron sparing surgery) has been performed widely with great success. It is usually performed when the tumours are clinically localized and the size of the tumor is 6cm or less (Stage 1A and possibly stage 1B) [2,21,24,25].…”

Section: Treatmentmentioning

confidence: 99%

“…In patients with the renal transplant; malignancies of the urinary tract is the second most common following skin tumours. The most affected organs are prostate, kidneys, bladder and testes [2]. Diagnosis of tumours in renal allograft are usually accidental following ultrasonography, CT scan or MRI imaging, so special attention is essential during imaging examination of renal allograft to detect any probable tumor at early stage [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Case Report: Renal Cell Carcinoma of First Kidney Allograft in Transplanted Recipient for Second Time

Alnour¹,

Alalawi²,

Khalifa³

et al. 2016

UNOAJ

View full text Add to dashboard Cite

The uses of immunosuppressive therapy to preserve the new allograft function can significantly increases the incidence of malignancies in transplanted recipients compared with that of general population. The ability to identify and prevent solid organ tumours in the transplant patients, particularly early stages carcinomas depends on regular screening examinations and strict adherence to prophylactic measures. Screening of the patient and donor prior to transplant can help to detect any underlying pre-existing malignancy. Identification of tumor in renal allograft are usually accidental following ultrasonography, CT scan or MRI imaging, so special attention is essential during any imaging examination of renal allograft to detect an early probable tumours.We hereby, present a case record of 51 years old male who had his first kidney transplant in 1987 on the right side from living unrelated donor; he had approached ESRD in 2006 and underwent his second renal transplantation in June 2006 on the left side from living unrelated donor. Though he had stable kidney function, he started to have intermittent haematuria with lump at right lower loin. Allograft sonography had revealed a big mass in the first right transplanted kidney. CT scan with contrast demonstrated a large lobulated enhancing mass arising from the iliac fossa of first transplanted kidney with local, right common iliac vein metastasis and lungs metastasis. Due to above finding patient underwent right allograft nephrectomy.

show abstract

“…1 The data suggest the prevalence of renal cell carcinoma (RCC) in the native kidney of renal transplant recipients. [2][3][4][5] The reported incidence of de novo RCC in native kidney varies between 0.3% to 4.8%. 6 Several risk factors have been suggested including duration and type of immunosuppression, native kidney disease, recipient/donor age, pretransplant dialysis time, and microscopic hematuria.…”

Section: Introductionmentioning

confidence: 99%

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Karczewski

Rzymski²,

Karczewski³

2012

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Our study aimed to determine the incidence of de novo renal cell carcinoma in the native kidneys of patients transplanted at our center and to identify possible risk factors. Materials and Methods: We performed a retrospective, single-center cohort study, which included patients transplanted at the District Hospital in Poznan, Poland, during 1994-2011, among whom 836 were selected. Sixty-three patients with confirmed de novo cancer were found. Of those, 11 had renal cell carcinoma in the native kidney (1.3%) and 2 in the transplanted kidney (0.2%). Results: Mean follow-up was 10 ± 3.2 years. Mean age at renal cell carcinoma diagnosis was 52 ± 9.4 years, and mean time from transplant was 3 ± 2.6 years. A statistical analysis showed no significant differences in demographic or clinical characteristics between renal cell carcinoma and noncancer group, except for the prevalence of male sex and smoking in the cancer group (P < .05). Conclusions: Renal cell carcinoma development in the native kidney seems to be an early event, frequently observed within 4 to 5 years after transplant. We believe that kidneys in renal transplant recipients should be routinely screened by ultrasound for early diagnosis.

show abstract

Renal Cell Carcinoma in Renal Transplant Patients

Cited by 59 publications

References 9 publications

Uncommon and recently described renal carcinomas

Uncommon and recently described renal carcinomas

Case Report: Renal Cell Carcinoma of First Kidney Allograft in Transplanted Recipient for Second Time

De Novo Renal Cell Carcinoma of Native Kidneys in Renal Transplant Recipients: A Single-Center Experience

Contact Info

Product

Resources

About